The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
The Search for Effective Therapy for Sepsis: Back to the Drawing Board?
Abstract
NEW THERAPEUTIC APPROACHES FOR SEPSIS HAVE NOT fared well recently. In January, Eisai announced that its worldwide phase 3 randomized trial of a novel anti–Toll-like receptor (TLR)-4 compound, eritoran tetrasodium, had failed to demonstrate an improvement in the primary end point of 28-day all-cause mortality in a cohort of 2000 patients with severe sepsis. This news was disappointing, especially because the manipulation of TLR4 signaling would represent a new avenue of research and drug development. Perhaps ironically, only a few months later, the importance of TLR4 signaling was recognized with the award of the Nobel Prize in Physiology or Medicine to Jules Hoffmann and Bruce Beutler for their work in this area. In October, Eli Lilly announced it was withdrawing Xigris (drotrecogin alfa, a recombinant activated protein C) from the market following the failure of its worldwide trial, PROWESS Shock, to demonstrate improved outcome. Drotrecogin alfa, the only approved drug specifically indicated for the treatment of severe sepsis, had been approved on the basis of an earlier trial, PROWESS, which had demonstrated a large improvement in survival. That the findings were not confirmed by the subsequent trial was another major disappointment. So what now? At a minimum, researchers and clinicians need to rethink the therapeutic approach to sepsis. Some obvious questions come to mind. First, is the current understanding of the pathophysiology of sepsis flawed in some important way? Second, is the current approach to the discovery and evaluation of potential therapies in need of overhaul? Third, assuming the answer is yes to either of these questions, where should researchers go next? Sepsis is a broad term, with its roots in the writings of Hippocrates. At its heart is the concept of a patient fighting to survive a life-threatening infection. And it is the fight that is thought to be injurious. The invading pathogen can be directly toxic and destructive to tissue, but much of the pathology associated with sepsis is attributed to the host response. Host immune cells exposed to pathogenassociated molecular patterns (PAMPs), such as lipopolysaccharide (LPS), rapidly produce a broad array of cytokines, chemokines, and other proteins to sequester and eradicate invading pathogens. However, these same proteins can profoundly disturb and harm host tissue function and anatomy, a form of “friendly fire.” These findings led to 2 central tenets of current sepsis research. First, the host response in sepsis is unhelpfully exuberant, and thus agents that block or suppress the host response should improve outcome. Second, the host response represents a “final common pathway,” and thus agents that manipulate this pathway should work regardless of the source of infection. Neither tenet may be true. The host response does not appear to be ubiquitously overexuberant. Indeed, patients with similar signs and symptoms can have widely different cytokine profiles. As noted in the report by Boomer et al in this issue of JAMA, the host response can be dramatically suppressed rather than overly exuberant. Second, the discovery of PAMP-induced host response has helped highlight that host-pathogen interactions are much more sophisticated and nuanced than previously recognized. In short, there may not be a “final common pathway.” Current preclinical experiments and clinical trials of potential therapies account only partially for these observations. Preclinical animal experiments may be too simplistic. The animals are usually young and have no comorbidity. In contrast, patients with sepsis are often older and have underlying comorbidity, both of which are strong predictors of sepsis susceptibility and outcome. The insult in animal models is typically LPS, cecal ligation and puncture, or instillation of live bacteria into the lung to induce pneumonia, but formal evaluation of differences in response across these different infectious challenges is not usually done. Antibiotics are often not given in animal models, and there is little or no supportive care for the ensuing organ dysfunction. The ideal host response to fight infection in the absence of antibiotics and life support may be very different from that required in a modern intensive care unit setting. It would also be helpful to evaluate how a drug works in an animal model in terms of the effect on the immune system
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
Bernard, G. R., Vincent, J.-L., Laterre, P.-F., LaRosa, S. P., Dhainaut, J.-F., Lopez-Rodriguez, A., Steingrub, J. S., Garber, G. E., Helterbrand, J. D., Ely, E. W., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103083441001 · Cited by 6,132
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
Levy, M. M., Fink, M. P., Marshall, J. C., Abraham, E., Angus, D., Cook, D., Cohen, J., Opal, S. M., Vincent, J.-L., & Ramsay, G. (2003) · Critical Care Medicine · doi:10.1097/01.ccm.0000050454.01978.3b · Cited by 5,995
Self-citationImmunosuppression in Patients Who Die of Sepsis and Multiple Organ Failure
Boomer, J. S., To, K., Chang, K. C., Takasu, O., Osborne, D. F., Walton, A. H., Bricker, T. L., Jarman, S. D., Kreisel, D., Krupnick, A. S., et al. (2011) · JAMA · doi:10.1001/jama.2011.1829 · Cited by 1,781
Levy, M. M., Dellinger, R. P., Townsend, S. R., Linde-Zwirble, W. T., Marshall, J. C., Bion, J., Schorr, C., Artigas, A., Ramsay, G., Beale, R., et al. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181cb0cdc · Cited by 950
Self-citationKellum, J. A. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.15.1655 · Cited by 828
Host–pathogen interactions in sepsis
van der Poll, T., & Opal, S. M. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70265-7 · Cited by 553
The Lingering Consequences of Sepsis: A Hidden Public Health Disaster?
Angus, D. C. (2010) · JAMA · doi:10.1001/jama.2010.1546 · Cited by 159
Self-citation
Cited by
Severe Sepsis and Septic Shock
Angus, D. C., & van der Poll, T. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1208623 · Cited by 3,961
Self-citationSepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy
Hotchkiss, R. S., Monneret, G., & Payen, D. (2013) · Nature Reviews Immunology · doi:10.1038/nri3552 · Cited by 2,772
Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach
Hotchkiss, R. S., Monneret, G., & Payen, D. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70001-x · Cited by 1,442
Sepsis: a roadmap for future research
Cohen, J., Vincent, J.-L., Adhikari, N. K. J., Machado, F. R., Angus, D. C., Calandra, T., Jaton, K., Giulieri, S., Delaloye, J., Opal, S., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)70112-x · Cited by 992
Self-citationScicluna, B. P., van Vught, L. A., Zwinderman, A. H., Wiewel, M. A., Davenport, E. E., Burnham, K. L., Nürnberg, P., Schultz, M. J., Horn, J., Cremer, O. L., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30294-1 · Cited by 672
Metadata
- Authors
- Angus, D. C.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2011-12-21
- Volume
- 306
- Issue
- 23
- Pages
- 2614
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2048674276
- Cited by
- 264
- References
- 7
- FWCI
- 16.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.